Posted from: Monday, June 04, 2018 - 11:03 AM - Present

First CGRP Drug Approved to Prevent Migraines

May 17, 2018 – The U.S. FDA has approved Aimovig™ (erenumab-aooe), manufactured by Amgen and Novartis. The first in a new class of drugs, Aimovig is indicated to prevent migraines in adults.

Patients who suffer from migraines may produce too much of a protein fragment known as calcitonin gene-related peptide (CGRP). Drugs like Aimovig have the potential to reduce the number of migraine days these patients experience by keeping some CGRP from reaching receptors in the body. In clinical studies, patients treated with Aimovig had 1 to 2.5 fewer migraine days per month.

Aimovig is self-administered once each month via the SureClick® auto-injector, at 70mg per injection. In some instances, physicians may prescribe 140mg per monthly dose, based on individual patient needs.

Although the first in its class, Aimovig may soon face competition from other drugs in the CGRP antagonist class currently in development or awaiting FDA approval.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Wednesday, August 15, 2018 - 02:12 PM.